# US 9,750,772 B2 · Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,772 B2
- Document ID: US9750772B2
- Status: Granted
- Kind: B2
- Application number: 14/880,135
- Filed: 2015-10-09
- Published: 2016-05-12
- Granted: 2017-09-05
- Earliest claimed: 2005-09-27
- Assignees: Tissuetech, Inc.
- Applicants: TissueTech, Inc.
- Inventors: Scheffer Tseng; Hua He; Wei Li
- Web page: https://patentgrep.com/patent/US9750772B2

## CPC

- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/728: Hyaluronic acid
- A61K 31/738: Cross-linked polysaccharides
- A61K 35/48: Reproductive organs
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1709: {from mammals}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

## Claims

### Claim 1

A method of reducing angiogenesis in an individual in need thereof, comprising administering to the individual a composition comprising a water-soluble extract of amniotic membrane from frozen or previously frozen placenta, wherein the water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and cross-linked high molecular weight hyaluronan (HA).

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual has an angiogenesis-related disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the angiogenesis-related disease is tumor, cancer or an ophthalmological condition.

### Claim 4 (depends on 3)

The method of claim 3, wherein the ophthalmological condition is corneal graft rejection, ocular neovascularization, retinal neovascularization, diabetic retinopathy, macular degeneration, retrolental fibroplasia, neovascular glaucoma, retinal ischemia, or vitreous hemorrhage.

### Claim 5 (depends on 3)

The method of claim 3, wherein the tumor or cancer is acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, bronchial adenomas, Burkitt's lymphoma, carcinoid tumor, carcinoma, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, extragonadal germ cell tumor, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), extracranial germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, Hodgkin's lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemia, lip and oral cavity cancer, liver cancer, non-small cell lung cancer, small cell lung cancer, lymphoma, non-Hodgkin's lymphoma, medulloblastoma, melanoma, Merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative diseases, myelogenous leukemia, myeloid leukemia, myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma/malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancreatic cancer, parathyroid cancer, penile cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, retinoblastoma, rhabdomyo sarcoma, salivary gland cancer, sarcoma, Sezary syndrome, non-melanoma skin cancer, Merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, testicular cancer, thymoma, thyroid cancer, trophoblastic tumor, gestational cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, visual pathway and hypothalamic glioma, vulvar cancer, Waldenström's Macroglobulinemia, or Wilms' tumor.

### Claim 6 (depends on 1)

The method of claim 1, wherein the extract further comprises Smad7.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable diluent, excipient, carrier, or combination thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition is formulated as a non-solid dosage form, a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, shampoo, or combination thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration.

### Claim 10 (depends on 7)

The method of claim 7, wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjuctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, implantation, ocular implantation, or ocular insertion.

### Claim 11 (depends on 7)

The method of claim 7, wherein the composition further comprises a penetration enhancer and an aqueous adjuvant.

### Claim 12 (depends on 7)

The method of claim 7, wherein the composition is formulated as a solid dosage form.

### Claim 13 (depends on 7)

The method of claim 7, wherein the composition is formulated for controlled release.